nach oben

Inflammopharmacology

Erschienen in:

12.03.2018 | Review

Predicting methotrexate resistance in rheumatoid arthritis patients

verfasst von: Mary Beth Yu, Anthony Firek, William H. R. Langridge

Erschienen in: Inflammopharmacology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) is an incurable, systemic autoimmune disease that decreases quality of life and can lead to severe disability. While there are many medications available to treat RA, the first-line of therapy is low-dose methotrexate (MTX), a small molecule disease-modifying anti-rheumatic drug (DMARD). MTX is the recommended therapy due to its affordability and efficacy in reducing symptoms in most RA patients. Unfortunately, there is great person-to-person variability in the physiological response to MTX, with up to 50% of patients showing little response to the medication. Thus, many RA patients initially placed on MTX do not experience an adequate reduction of symptoms, and could have benefited more in both the short and long terms if initially prescribed a different drug that was more effective for them. To combat this problem and better guide treatment decisions, many research groups have attempted to develop predictive tools for MTX response. Currently, there is no reliable, clinical-grade method to predict an individual’s response to MTX treatment. In this review, we describe progress made in the area of MTX non-response/resistance in RA patients. We specifically focus on application of the following elements as predictive markers: proteins related to MTX transport and function, intracellular MTX concentration, immune cell frequencies, cytokines, and clinical factors.

Al-Dabagh A, Davis SA, Kinney MA, Huang K, Feldman SR (2013) The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. Am J Clin Dermatol 14:155–161. https://doi.org/10.1007/s40257-013-0017-9 CrossRefPubMed

Ally MM, Hodkinson B, Meyer PW, Musenge E, Tintinger GR, Tikly M, Anderson R (2015) Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. BMC Musculoskelet Disord 16:130. https://doi.org/10.1186/s12891-015-0587-1 CrossRefPubMedPubMedCentral

Angelis-Stoforidis P, Vajda FJ, Christophidis N (1999) Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 17:313–320PubMed

Antonioli L, Pacher P, Vizi ES, Haskó G (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med 19:355–367. https://doi.org/10.1016/j.molmed.2013.03.005 CrossRefPubMedPubMedCentral

Benito-Garcia E et al (2006) Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol 33:1275–1281PubMed

Bohanec Grabar P, Logar D, Lestan B, Dolzan V (2008) Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 64:1057–1068. https://doi.org/10.1007/s00228-008-0521-7 CrossRefPubMed

Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac’h N, Falgarone G (2012) Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 39:222–228. https://doi.org/10.1016/j.jaut.2012.05.021 CrossRefPubMed

Braun J et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58:73–81. https://doi.org/10.1002/art.23144 CrossRefPubMed

Budzik GP, Colletti LM, Faltynek CR (2000) Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line. Life Sci 66:2297–2307CrossRefPubMed

Chara L et al (2015) The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis. J Transl Med 13:2. https://doi.org/10.1186/s12967-014-0375-y CrossRefPubMedPubMedCentral

Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163–172. https://doi.org/10.1124/pr.57.2.3 CrossRefPubMed

Dervieux T (2009) Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability. Rheumatology (Oxford) 48:597–598. https://doi.org/10.1093/rheumatology/kep060 CrossRef

Dhir V, Sandhu A, Gupta N, Dhawan V, Sharma S, Sharma A (2013) Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis. ISRN Inflamm 2013:460469. https://doi.org/10.1155/2013/460469 CrossRefPubMedPubMedCentral

Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M (2006) The effect of 3435C > T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62:933–937. https://doi.org/10.1007/s00228-006-0192-1 CrossRefPubMed

Fransen J, Kooloos WM, Wessels JA, Huizinga TW, Guchelaar HJ, van Riel PL, Barrera P (2012) Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics 13:1087–1094. https://doi.org/10.2217/pgs.12.83 CrossRefPubMed

Furumiya M et al (2014) Noncompetitive inhibition of proton-coupled folate transporter by myricetin. Drug Metab Pharmacokinet 29:312–316CrossRefPubMed

Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 42:1189–1196. https://doi.org/10.1093/rheumatology/keg323 CrossRef

Haroon N, Srivastava R, Misra R, Aggarwal A (2008) A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression. J Rheumatol 35:975–978PubMed

Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770. https://doi.org/10.1038/nrd2638 CrossRefPubMedPubMedCentral

Herman S, Zurgil N, Deutsch M (2005) Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 54:273–280. https://doi.org/10.1007/s00011-005-1355-8 CrossRefPubMed

Hooijberg JH et al (2014) Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1). Cancer Chemother Pharmacol 73:911–917. https://doi.org/10.1007/s00280-014-2421-0 PubMedCrossRef

Hryniuk WM, Brox LW, Henderson JF, Tamaoki T (1975) Consequences of methotrexate inhibition of purine biosynthesis in L5178Y cells. Cancer Res 35:1427–1432PubMed

Inoue K, Yuasa H (2014) Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet 29:12–19CrossRefPubMed

Kato T, Hamada A, Mori S, Saito H (2012) Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 27:192–199CrossRefPubMed

Klareskog L et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681. https://doi.org/10.1016/s0140-6736(04)15640-7 CrossRefPubMed

Kremer JM (2004) Toward a better understanding of methotrexate. Arthritis Rheum 50:1370–1382. https://doi.org/10.1002/art.20278 CrossRefPubMed

Kremer JM, Galivan J, Streckfuss A, Kamen B (1986) Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29:832–835CrossRefPubMed

Kulier R, Kapp N, Gulmezoglu AM, Hofmeyr GJ, Cheng L, Campana A (2011) Medical methods for first trimester abortion. Cochrane Database Syst Rev 2011:Cd002855. https://doi.org/10.1002/14651858.CD002855.pub4 CrossRef

Lima A, Bernardes M, Azevedo R, Medeiros R, Seabra V (2015) Pharmacogenomics of Methotrexate Membrane Transport Pathway: can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? Int J Mol Sci 16:13760–13780. https://doi.org/10.3390/ijms160613760 CrossRefPubMedPubMedCentral

Ma MH et al (2012) Remission in early rheumatoid arthritis: predicting treatment response. J Rheumatol 39:470–475. https://doi.org/10.3899/jrheum.110169 CrossRefPubMed

Maillefert JF et al (2010) Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. Joint Bone Spine 77:558–563. https://doi.org/10.1016/j.jbspin.2010.02.018 CrossRefPubMed

McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219. https://doi.org/10.1056/NEJMra1004965 CrossRefPubMed

Micsik T, Lorincz A, Gal J, Schwab R, Petak I (2015) MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients. Diagn Pathol 10:216. https://doi.org/10.1186/s13000-015-0447-1 CrossRefPubMedPubMedCentral

Mori S, Hirose J, Yonemura K (2010) Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis. Clin Rheumatol 29:1357–1366. https://doi.org/10.1007/s10067-010-1454-y CrossRefPubMed

Muralidharan N, Antony PT, Jain VK, Mariaselvam CM, Negi VS (2015) Multidrug resistance 1 (MDR1) 3435C > T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. Eur J Clin Pharmacol 71:959–965. https://doi.org/10.1007/s00228-015-1885-0 CrossRefPubMed

Nesher G, Mates M, Zevin S (2003) Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 48:571–572. https://doi.org/10.1002/art.10766 CrossRefPubMed

Patro PS, Singh A, Misra R, Aggarwal A (2016) Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: marker of Disease Activity and Response to Methotrexate. J Rheumatol 43:731–737. https://doi.org/10.3899/jrheum.150998 CrossRefPubMed

Peres RS et al (2015) Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. Proc Natl Acad Sci U S A 112:2509–2514. https://doi.org/10.1073/pnas.1424792112 CrossRefPubMedPubMedCentral

Ponchel F et al (2014) An immunological biomarker to predict MTX response in early RA. Ann Rheum Dis 73:2047–2053. https://doi.org/10.1136/annrheumdis-2013-203566 CrossRefPubMed

Prasad S, Tripathi D, Rai MK, Aggarwal S, Mittal B, Agarwal V (2014) Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate. Int J Rheum Dis 17:878–886. https://doi.org/10.1111/1756-185x.12362 CrossRefPubMed

Ranganathan P et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572–579PubMed

Saevarsdottir S et al (2011a) Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 70:469–475. https://doi.org/10.1136/ard.2010.139212 CrossRefPubMed

Saevarsdottir S et al (2011b) Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 63:26–36. https://doi.org/10.1002/art.27758 CrossRefPubMed

Sakowicz-Burkiewicz M, Kocbuch K, Grden M, Maciejewska I, Szutowicz A, Pawelczyk T (2012) Impact of adenosine receptors on immunoglobulin production by human peripheral blood B lymphocytes. J Physiol Pharmacol 63:661–668PubMed

Seitz M, Zwicker M, Villiger PM (2003) Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate. J Rheumatol 30:28–35PubMed

Sharma S et al (2008) Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 18:1041–1049CrossRefPubMed

Sharma S et al (2009) Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics 19:823–828CrossRefPubMed

Shea B et al (2013) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013:Cd000951. https://doi.org/10.1002/14651858.CD000951.pub2 CrossRef

Shurin GV, Tourkova IL, Kaneno R, Shurin MR (2009) Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183:137–144. https://doi.org/10.4049/jimmunol.0900734 CrossRefPubMedPubMedCentral

Singh JA et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 68:1–25. https://doi.org/10.1002/acr.22783 CrossRef

Smolen JS et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715 CrossRefPubMed

Stamp LK et al (2010) Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics 20:367–376. https://doi.org/10.1097/FPC.0b013e3283398a71 CrossRefPubMed

Stamp LK, Hazlett J, Highton J, Hessian PA (2013) Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue. J Rheumatol 40:1519–1522. https://doi.org/10.3899/jrheum.130066 CrossRefPubMed

Takatori R et al (2006) ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 24:546–554PubMed

Tazoe Y et al (2015) Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 30:227–230. https://doi.org/10.1016/j.dmpk.2015.02.001 CrossRefPubMed

Tian H, Cronstein BN (2007) Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 65:168–173PubMed

van der Heijden JW et al (2009) Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum 60:669–677. https://doi.org/10.1002/art.24354 CrossRefPubMed

Visser K et al (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086–1093. https://doi.org/10.1136/ard.2008.094474 CrossRefPubMed

Weinblatt ME et al (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492–1498CrossRefPubMed

Wessels JA et al (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56:1765–1775. https://doi.org/10.1002/art.22640 CrossRefPubMed

Wevers-de Boer K et al (2012) Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 71:1472–1477. https://doi.org/10.1136/annrheumdis-2011-200736 CrossRefPubMed

Wijngaarden S, van Roon JA, van de Winkel JG, Bijlsma JW, Lafeber FP (2005) Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. Rheumatology (Oxford) 44:729–734. https://doi.org/10.1093/rheumatology/keh583 CrossRef

Witte T (2015) Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint? Clin Rheumatol 34:629–634. https://doi.org/10.1007/s10067-015-2861-x CrossRefPubMedPubMedCentral

Wolf J, Stranzl T, Filipits M, Pohl G, Pirker R, Leeb B, Smolen JS (2005) Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis 64:564–568. https://doi.org/10.1136/ard.2003.014985 CrossRefPubMed

Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81:646–656PubMedPubMedCentral

Yu X, Wang C, Luo J, Zhao X, Wang L, Li X (2013) Combination with methotrexate and cyclophosphamide attenuated maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo. Clin Dev Immunol 2013:238035. https://doi.org/10.1155/2013/238035 PubMedPubMedCentralCrossRef

Yuasa H, Inoue K, Hayashi Y (2009) Molecular and functional characteristics of proton-coupled folate transporter. J Pharm Sci 98:1608–1616. https://doi.org/10.1002/jps.21515 CrossRefPubMed

Yue C et al (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30:1553–1557. https://doi.org/10.1007/s00296-009-1179-x CrossRefPubMed

Zhu H, Deng FY, Mo XB, Qiu YH, Lei SF (2014) Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharmacogenomics 15:551–566. https://doi.org/10.2217/pgs.14.25 CrossRefPubMed

Titel: Predicting methotrexate resistance in rheumatoid arthritis patients
verfasst von: Mary Beth Yu
Anthony Firek
William H. R. Langridge
Publikationsdatum: 12.03.2018
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 3/2018
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-018-0459-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Effect of simvastatin on sensorial, motor, and morphological parameters in sciatic nerve crush induced-neuropathic pain in rats

Foeniculum vulgare essential oil ameliorates acetic acid-induced colitis in rats through the inhibition of NF-kB pathway

Emerging role of semaphorin-3A in autoimmune diseases

Silymarin mitigates lung impairments in a rat model of acute respiratory distress syndrome

Ziziphus spina-christi leaf extract pretreatment inhibits liver and spleen injury in a mouse model of sepsis via anti-oxidant and anti-inflammatory effects

Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis